



National Influenza Vaccine Summit

CSL Biotherapies Influenza Vaccine

2008-2009 Season

Ronan W. Gannon

Vice President, Marketing

US Commercial Operations

May 12-13, 2008

CSL Biotherapies

CSL's Flu Vaccine Business

- Global headquarters: Parkville, Australia
 - US headquarters: King of Prussia, PA
- Flu vaccines sold in 17 countries worldwide
 - Afluria approved by FDA in September 2007
- Annual capacity: 40 million doses
- Primarily prefilled syringes, preservative free
- Thimerosal withdrawn from bulk manufacturing process
- Latex free



CSL Biotherapies

We manufacture for Southern and Northern hemispheres, year round



- Committed to consistently developing flu vaccines based on strains changes decided by WHO and FDA
 - Expertise in early prediction of strains changes - ahead of official regulatory decisions e.g., 2008/09
 - H1N1 'Brisbane 59-like' strain was anticipated by CSL and can be produced
 - H3 N2 'Brisbane 10-like' strain
 - B 'Florida – like' strain
 - Early planning and improvement of our yields to allow early delivery to market
- } previously used in Southern Hemisphere '08 vaccine

Afluria[®]: Thimerosal-free, latex-free



CSL Biotherapies



A NEW FLU VACCINE FROM A RELIABLE SOURCE.

The Word Is Out. Pass It On.

Now there's a new vaccine to help protect your patients and your community from flu...all season long.

- **Thimerosal-free** and **latex-free*** (CPT[®] code 90656)
- **Convenient**, single-use, prefilled syringe delivery
- **Reliable availability** throughout the flu season
- **From a trusted influenza vaccine manufacturer** with 40 years' experience

Important Safety Information

Afluria[®] is indicated for active immunization of persons 18 years of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. The indication is based on the immune response elicited by Afluria[®]; no controlled clinical studies have demonstrated a decrease in influenza disease after vaccination with Afluria[®].

Afluria[®] should not be administered to individuals with hypersensitivity to eggs or chicken protein or other components of Afluria[®], or to anyone who has had a life-threatening reaction to previous influenza vaccination.

The most common injection-site adverse reactions were tenderness, pain, redness, and swelling. The most common systemic adverse reactions were headache, malaise, and muscle aches.

Vaccination with Afluria[®] may not protect all individuals. Immunocompromised persons may have a diminished immune response. If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give Afluria[®] should be based on careful consideration of the potential benefits and risks.

Please see brief summary of full prescribing information on adjacent page.

*Afluria[®] is also available in a latex-free, multidose vial formulation containing thimerosal as a preservative (CPT[®] code 90658).

[†]CPT is a registered trademark of the American Medical Association.



For a list of authorized distributors, call **1-888-4FLU-OFF** (1-888-435-8633).

To learn more about new Afluria[®], visit www.afluria.com.


© 2007 CSL Biotherapies, Inc., 1020 First Avenue, PO Box 60446, King of Prussia, PA 19406-0901 www.cslobiotherapies-us.com Printed in USA BF009 10/2007

Introducing
afluria.
influenza virus vaccine

CSL's Commitment to Public Health



Health care worker
vaccination 2006



You take care of everyone else.
Now take care of yourself.

Get immunized against influenza.

Because you work in a healthcare setting, you are at an increased risk for acquiring and transmitting the influenza virus— regardless of what your actual job is. By getting a flu vaccine, you're helping yourself and the patients around you.

For more information, go to www.nfid.org.

National Foundation for Infectious Diseases

CSL Biotherapies

The advertisement features a photograph of five healthcare professionals (three men and two women) in various medical attire (scrubs, lab coats, and business attire) standing in a line. Below the photo is a blue banner with white text, followed by a white section with black text, and a footer with logos for the National Foundation for Infectious Diseases and CSL Biotherapies.

CSL Biotherapies


CSL's Commitment to Public Health



- American College Health Association(2006): Flu is major impediment (26%) to academic performance
- ‘Season Pass’: Turn-key educational & motivational program to increase immunization rates on College Campuses
- **Season Pass impact: + 40% increase !**

Arizona State University

Medscape® www.medscape.com



CSL Biotherapies



Afluria 2008-2009 Season

- Our goal is to distribute 6 million doses
- 90% in thimerosal-free prefilled syringes
- First market deliveries expected in late August, early September
- Continue patient advocacy, educational programs to underscore the importance of influenza prevention

Our Short-Term Plans



- Afluria pediatric indication is a priority
 - clinical trials with thimerosal free prefilled syringe
 - pediatric indication granted by TGA in 2007
- Coming soon: fast filling syringe line - Kankakee, Ill.



Other Vaccine Activities



Gardasil

- Based on CSL technology licensed to Merck
- GARDASIL® is marketed by CSL Biotherapies in Australia and NZ

Iscomatrix™ adjuvant

- Provides both antigen delivery and immunomodulatory properties
- Antigen dose reduction properties
- Manufactured in Kankakee, IL plant
- Multiple partners and applications

In Summary...



- We have reliably produced safe flu vaccines over four decades
- CSL Biotherapies will contribute to meeting the U.S. growing demand for reliable flu vaccine each year



Thank you

CSL Biotherapies